alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 32.3





CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



In connection with the Quarterly Report of Thanksgiving Coffee Company, Inc. (the Company) on Form 10-Q for the quarter ended June 30, 2004 as filed with the
Securities and Exchange Commission on the date hereof (the Report), I, the undersigned Chief Financial Officer of the Company hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that:



| | (i) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
| | --- | ---------------------------------------------------------------------------------------------------------------------



| | (ii) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| | ---- | ----------------------------------------------------------------------------------------------------------------------------------------------------



/s/ Sam KraynekChief Financial OfficerAugust 12, 2004
EXHIBIT 31.2CERTIFICATIONI, Robert L. Miller, certify that: 1. I have reviewed this report on Form 10-QSB of CVF Technologies Corporation;  2. Based on my knowledge, this quarterly report does not contain any untrue statement ofa material fact or omit to state a material fact necessary to make the statements made, inlight of the circumstances under which such statements were made, not misleading withrespect to the period covered by this report;  3. Based on my knowledge, the financial statements, and other financial informationincluded in this report, fairly present in all material respects the financial condition,results of operations and cash flows of the registrant as of, and for, the periodspresented in this report;  4. The registrant’s other certifying officer and I are responsible for establishing andmaintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)and 15d-15(e)for the registrant and have: a. designed such disclosure controls and procedures, or caused suchdisclosure controls and procedures to be designed under our supervision, to ensurethat material information relating to the registrant, including its consolidatedsubsidiaries, is made known to us by others within those entities, particularlyduring the period in which this report is being prepared;  b. evaluated the effectiveness of the registrant’s disclosure controls and procedures andpresented in this report our conclusions about the effectiveness of the disclosure controls andprocedures, as of the end of the period covered by this report based on such evaluation; and  c. disclosed in this report any change in the registrant’s internal control over financialreporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fiscalfourth quarter in the case of an annual report) that has materially affected, or is reasonablylikely to materially affect, the registrant’s internal control over financial reporting; and 5. The registrant’s other certifying officer and I have disclosed, based on our most recentevaluation of internal control over financial reporting, to the registrant’s auditors and the auditcommittee of registrant’s board of directors (or persons performing the equivalent functions): a. all significant deficiencies and material weaknesses in the design or operation of whichare reasonably likely to adversely affect the registrant’s ability to record, process, summarizeand report financial information; and  b. any fraud, whether or not material, that involves management or other employees whohave a significant role in the registrant’s internal control over financial reporting.Date: August 14, 2007              /s/ Robert L. Miller   Robert L. Miller,   Chief Financial Officer
<TABLE> <S> <C>


<ARTICLE>                     5

<S>                             <C>
<PERIOD-TYPE>                            3-MOS
<FISCAL-YEAR-END>                  FEB-28-2000
<PERIOD-END>                       NOV-30-2000
<CASH>                                  14,976
<SECURITIES>                                 0
<RECEIVABLES>                          244,889
<ALLOWANCES>                            52,200
<INVENTORY>                          1,496,643
<CURRENT-ASSETS>                     1,931,964
<PP&E>                                 509,498
<DEPRECIATION>                         271,000
<TOTAL-ASSETS>                       2,232,503
<CURRENT-LIABILITIES>                  689,999
<BONDS>                                      0
<PREFERRED-MANDATORY>                        0
<PREFERRED>                                  3
<COMMON>                                 4,947
<OTHER-SE>                           1,373,558
<TOTAL-LIABILITY-AND-EQUITY>         2,232,503
<SALES>                                 76,360
<TOTAL-REVENUES>                        76,360
<CGS>                                  143,513
<TOTAL-COSTS>                          143,513
<OTHER-EXPENSES>                       272,084
<LOSS-PROVISION>                      (339,238)
<INTEREST-EXPENSE>                     (28,586)
<INCOME-PRETAX>                       (367,824)
<INCOME-TAX>                          (367,824)
<INCOME-CONTINUING>                   (367,824)
<DISCONTINUED>                               0
<EXTRAORDINARY>                              0
<CHANGES>                                    0
<NET-INCOME>                          (367,824)
<EPS-BASIC>                            (0.14)
<EPS-DILUTED>                            (0.14)



</TABLE>
<PAGE>


                                                                    EXHIBIT 23.1


  CONSENT OF ERNST & YOUNG LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

      We consent to the incorporation by reference in the Registration
Statements on Form S-8 (No.'s 333-117116, 333-107416, 333-87266, 333-64238,
333-63950, 333-44852, 333-87759, 333-62437, 333-11577, 333-96302, 333-81236, and
333-44336) and Form S-3 (No.'s 333-114793, 333-109641 and 333-76544) of our
report dated February 18, 2005, with respect to the financial statements of
Epimmune Inc. included in the Annual Report (Amendment No. 1 to Form 10-K/A) for
the year ended December 31, 2004.

                                          /s/ ERNST & YOUNG LLP

San Diego, California
June 17, 2005
## State of N ew York Su p reme Cou rt, A p p ellate Division Third J u dicial Dep artment Decided and Entered: September 4, 2014 105482

________________________________ THE PEOPLE OF THE STATE OF NEW YORK, Respondent, v MEMORANDUM AND ORDER JAMES WAITE JR., Appellant.

________________________________ Calendar Date: August 21, 2014 Before: McCarthy, J.P., Garry, Egan Jr., Lynch and Clark, JJ.

__________ Erin C. Morigerato, Albany, for appellant. Alexander Lesyk, Special Prosecutor, Norwood, for respondent.

__________ Egan Jr., J. Appeal from a judgment of the County Court of St. Lawrence County (Richards, J.), rendered September 24, 2012, convicting defendant upon his plea of guilty of the crime of criminal possession of marihuana in the second degree. In full satisfaction of an indictment and other uncharged crimes, defendant pleaded guilty to criminal possession of marihuana in the second degree and waived his right to appeal. County Court thereafter sentenced defendant to two years in prison, followed by one year of postrelease supervision, to be served concurrently with the sentence defendant already was serving. Defendant now appeals.-2- 105482

We affirm. Defendant's challenge to the validity of his appeal waiver is without merit. Our review of the plea colloquy and the written waiver executed by defendant reveals that he was apprised of and understood the rights he was relinquishing, including the right to appeal his sentence. Accordingly, we conclude that defendant's waiver was knowing, intelligent and voluntary (see People v Newton, 113 AD3d 1000, 1000-1001 [2014], lvs denied ___ NY3d ___ [July 15, 2014]; People v Smith, 112 AD3d 1232, 1232 [2013], lv denied 22 NY3d 1203 [2014]). Although defendant's challenge to the voluntariness of his plea survives his appeal waiver, it is unpreserved for our review, inasmuch as the record does not reflect that defendant made an appropriate postallocution motion (see People v Trombley, 115 AD3d 1114, 1114 [2014]). Further, the narrow exception to the preservation rule was not implicated, as defendant did not make any statements during the plea colloquy that cast doubt upon his guilt or otherwise called into question the voluntariness of his plea (see People v Bressard, 112 AD3d 988, 989 [2013], lv denied 22 NY3d 1137 [2014]; People v Osgood, 111 AD3d 1029, 1030 [2013], lv denied 22 NY3d 1089 [2014]). Finally, defendant's contention that his sentence is harsh and excessive is precluded by his valid appeal waiver (see People v Campbell, 114 AD3d 996, 997 [2014]; People v Graves, 113 AD3d 998, 999 [2014], lv denied ___ NY3d ___ [July 14, 2014]). McCarthy, J.P., Garry, Lynch and Clark, JJ., concur.
ORDERED that the judgment is affirmed.

ENTER:

Robert D. Mayberger Clerk of the Court
**Exhibit 31.1**
**Sarbanes-Oxley Section 302 Certification**
I, Stephen J. Hansbrough, certify that:
1. I have reviewed this annual report on Form 10-K of HearUSA, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact oromit to state a material fact necessary to make the statements made, in light of the circumstancesunder which such statements were made, not misleading with respect to the period covered by thisreport;
3. Based on my knowledge, the financial statements, and other financial information included inthis report, fairly present in all material respects the financial condition, results ofoperations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintainingdisclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) forthe registrant and we have:
 a)  Designed such disclosure controls and procedures, or caused such disclosurecontrols and procedures to be designed under our supervision, to ensure that materialinformation relating to the registrant, including its consolidated subsidiaries, ismade known to us by others within those entities, particularly during the period inwhich this report is being prepared;  b)  Evaluated the effectiveness of the registrant’s disclosure controls andprocedures and presented in this report our conclusions about the effectiveness of thedisclosure controls and procedures, as of the end of the period covered by this reportbased on such evaluations; and  c)  Disclosed in this report any change in the registrant’s internal control overfinancial reporting that occurred during the registrant’s most recent fiscal quarter(the registrant’s fourth fiscal quarter in the case of an annual report) that hasmaterially affected, or is reasonably likely to materially affect, the registrant’sinternal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recentevaluation of internal control over financial reporting, to the registrant’s auditors and the auditcommittee of registrant’s board of directors (or persons performing the equivalent function):
 a)  All significant deficiencies and material weaknesses in the design or operationof internal control over financial reporting which are reasonably likely to adverselyaffect the registrant’s ability to record, process, summarize and report financialinformation; and  b)  Any fraud, whether or not material, that involves management or other employeeswho have a significant role in the registrant’s internal control over financialreporting.
Date: February 28, 2005
/s/Stephen J. Hansbrough
<TABLE> <S> <C>

<ARTICLE>                              5

<LEGEND> THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
HAGLER BAILLY, INC. UNAUDITED  CONSOLIDATED  FINANCIAL  STATEMENTS FOR THE NINE
MONTHS ENDED SEPTEMBER 30, 1997 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO
SUCH FINANCIAL STATEMENTS.
</LEGEND>

       
<S>                                            <C>    
<PERIOD-TYPE>                                         9-MOS
<FISCAL-YEAR-END>                               DEC-31-1997
<PERIOD-START>                                  JAN-01-1997
<PERIOD-END>                                    SEP-30-1997
<CASH>                                            3,269,910
<SECURITIES>                                              0
<RECEIVABLES>                                    28,805,845
<ALLOWANCES>                                      1,385,366
<INVENTORY>                                               0
<CURRENT-ASSETS>                                 46,000,282
<PP&E>                                            5,431,274
<DEPRECIATION>                                    2,565,607
<TOTAL-ASSETS>                                   57,191,791
<CURRENT-LIABILITIES>                            12,774,407
<BONDS>                                                   0
<PREFERRED-MANDATORY>                                     0
<PREFERRED>                                               0
<COMMON>                                             88,475
<OTHER-SE>                                       42,182,755
<TOTAL-LIABILITY-AND-EQUITY>                     57,191,791
<SALES>                                          26,530,840
<TOTAL-REVENUES>                                 26,530,840
<CGS>                                            20,244,029
<TOTAL-COSTS>                                    20,244,029
<OTHER-EXPENSES>                                          0
<LOSS-PROVISION>                                          0
<INTEREST-EXPENSE>                                  774,345
<INCOME-PRETAX>                                   2,732,184
<INCOME-TAX>                                        776,852
<INCOME-CONTINUING>                               1,955,332
<DISCONTINUED>                                            0
<EXTRAORDINARY>                                           0
<CHANGES>                                                 0
<NET-INCOME>                                      1,955,332
<EPS-PRIMARY>                                          0.22
<EPS-DILUTED>                                          0.20



        

</TABLE>
# EUR-Lex - 52006AP0073 - EN

Important legal notice

*|*

# 52006AP0073

**European Parliament legislative resolution on the proposal for a directive of the European Parliament and of the Council amending Council Directive 77/91/EEC as regards the formation of public limited liability companies and the maintenance and alteration of their capital (COM(2004)0730 - C6-0169/2004 - 2004/0256(COD)) **

*
Official Journal 291 E , 30/11/2006 P. 0085 - 0091 *

P6_TA(2006)0073

Formation and capital of public limited liability companies ***I

European Parliament legislative resolution on the proposal for a directive of the European Parliament and of the Council amending Council Directive 77/91/EEC as regards the formation of public limited liability companies and the maintenance and alteration of their capital (COM(2004)0730 — C6-0169/2004 — 2004/0256(COD))

(Codecision procedure: first reading)

The European Parliament,

- having regard to the Commission proposal to the European Parliament and the Council (COM(2004)0730) [1],

- having regard to Article 251(2) and Article 44(1) of the EC Treaty, pursuant to which the Commission submitted the proposal to Parliament (C6-0169/2004),

- having regard to Rule 51 of its Rules of Procedure,

- having regard to the report of the Committee on Legal Affairs and the opinion of the Committee on Economic and Monetary Affairs (A6-0050/2006),

1. Approves the Commission proposal as amended;

2. Calls on the Commission to refer the matter to Parliament again if it intends to amend the proposal substantially or replace it with another text;

3. Instructs its President to forward its position to the Council and Commission.

[1] Not yet published in OJ.

--------------------------------------------------
<TABLE> <S> <C>


                                   
<ARTICLE> 5
<LEGEND>
This  schedule  contains  summary  financial   information  extracted  from  the
Consolidated  Balance  Sheet  as at  September  30,  1997  and the  Consolidated
Statements  of Operations at September 30, 1996 and 1997 and is qualified in its
entirety by reference to such financial statements.
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          SEP-30-1997
<PERIOD-END>                               SEP-30-1997
<CASH>                                             579
<SECURITIES>                                         0
<RECEIVABLES>                                    3,821
<ALLOWANCES>                                       168
<INVENTORY>                                      1,879
<CURRENT-ASSETS>                                 7,045
<PP&E>                                           1,103
<DEPRECIATION>                                     644
<TOTAL-ASSETS>                                   8,036
<CURRENT-LIABILITIES>                            3,457
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                        675
<COMMON>                                             4
<OTHER-SE>                                           0
<TOTAL-LIABILITY-AND-EQUITY>                     8,036
<SALES>                                         16,029
<TOTAL-REVENUES>                                16,029
<CGS>                                           10,425
<TOTAL-COSTS>                                   15,127
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 242
<INCOME-PRETAX>                                    902
<INCOME-TAX>                                       100
<INCOME-CONTINUING>                                802
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                       802
<EPS-PRIMARY>                                      .12
<EPS-DILUTED>                                      .12





</TABLE>
Case: 1:01-cv-07013 Document #: 21 Filed: 07/15/02 Page 1 of 6 PageID #:119
Case: 1:01-cv-07013 Document #: 21 Filed: 07/15/02 Page 2 of 6 PageID #:120
Case: 1:01-cv-07013 Document #: 21 Filed: 07/15/02 Page 3 of 6 PageID #:121
Case: 1:01-cv-07013 Document #: 21 Filed: 07/15/02 Page 4 of 6 PageID #:122
Case: 1:01-cv-07013 Document #: 21 Filed: 07/15/02 Page 5 of 6 PageID #:123
Case: 1:01-cv-07013 Document #: 21 Filed: 07/15/02 Page 6 of 6 PageID #:124
Unassociated Document


    EXHIBIT 4.2

     

     

    
      	   	
               

              8
      Hartom St, Jerusalem Israel 97775

              Phone:
      +972-2-548-6555  Fax: +972-2-548-6550

              www.biocancell.com  info@biocancell.com

            


    

    


    Allocation
Letter No:

    


    To:


    


    


    To whom
it may concern,

    


    Re: Allocation Letter for
Series 2 Warrants of BioCancell Therapeutics, Inc,

    a Delaware Corporation (“the
Corporation”)

    


    This is
to inform you that [_______] Series 2 Warrants for the purchase of shares
of the stock of the Corporation (par value $0.01 each) are hereby allocated in
your name as per the prospectus of the Corporation of [_______] (“the
Prospectus”).

    


    Please
note that as established in the Prospectus, anyone exercising a Series 2 Warrant
will be considered to have declared that they are not a U.S. Person, are not in
the United States at the time of exercise, and are not exercising the Series 2
Warrant for a US Person and/or a person in the United States at the time of
exercise.

    


    This
allocation letter can be split, transferred or waived in accordance with the
terms of the Prospectus.

    


    The
allocated Series 2 Warrants will be recorded by the Corporation in its registry
of Series 2 Warrant-holders of the Corporation.

    


    Sincerely,

    


    


    


    
      
        
          
            
              
                
                  
                    
                      
                        	
                                /s/
      Avi Barak

                              	 
      	
                                /s/
      Ira Weinstein

                              	 
	
                                Avi
      Barak

                              	 
      	
                                Ira
      Weinstein

                              	 
	
                                Chief
      Executive Officer

                              	 
      	
                                Chief
      Financial Officer

                              	 
	
                                BioCancell
      Therapeutics, Inc.

                              	 
      	
                                BioCancell
      Therapeutics, Inc.
#### EDWARDS, Appellant, v. NIAGARA FIRE INS. CO., Respondent.

(Supreme Court, General Term, Third Department.

December 3, 1895.)

Action by John Edwards against the Niagara Fire Insurance Company.

No opinion. Judgment affirmed, with costs.
U.S. flagAn official website of the United States government
                    Here's how you know **Official websites use .gov**
                            
                            A **.gov** website belongs to an official government organization in the United States.
 **Secure .gov websites use HTTPS**
                            
                            A **lock** (                            
                              A locked padlock                                                      
                            
                            ) or **https://** means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.


Menu Agricultural Research Service
						
                    U.S. DEPARTMENT OF AGRICULTURE
 Agroecosystem Management Research: Lincoln, NE
 close



    Research

                    Research Projects
                                    Publications
                                    Collaborations
                                    News
                People

                    Staff Listing
                                    CareersSearch small
                    Search
            
            ARS Home
                                About ARS
                                Contact Us




ARS Home Plains Area Lincoln, Nebraska Agroecosystem Management Research People & Locations







Aidan G Galusha
                        Agroecosystem Management Research

                        




                        
                        Biological Science Aid
                        Phone: (402) 472-1511
                        
                        
                        Fax: (402) 472-4020(Employee information on this page comes from the REE Directory. Please contact your front office staff to update the REE Directory.)


Return to top


Connect with ARS Sign up


ARS Home
                            USDA.gov
                            Plain Writing
                            Policies & Links
                            Civil Rights Statements
                            FOIA
                            Accessibility Statement
                            Privacy Policy
                            Non-Discrimination Statement
                            Quality of Information
                            USA.gov
                            WhiteHouse.gov